Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Bondolfi, G. Articles by Baumann, P. Search for Related Content PubMed Citation Articles by Bondolfi, G. Articles by Baumann, P.

Risperidone Versus Clozapine in Treatment-Resistant Chronic Schizophrenia: A Randomized Double-Blind Study

OBJECTIVE: The purpose of this study was to compare the short-term efficacy and safety of risperidone and clozapine in treatment-resistant chronic schizophrenic patients. METHOD: In a controlled double-blind, multicenter study, 86 inpatients with chronic schizophrenia (DSM-III-R), who were resistant to or intolerant of conventional neuroleptics, were randomly assigned to receive risperidone or clozapine for 8 weeks after a 7-day washout period. After a 1-week dose-titration phase, doses were fixed at 6 mg/day of risperidone and 300 mg/day of clozapine for 1 week and then adjusted according to each patient's response. The final mean doses were 6.4 mg/day of risperidone and 291.2 mg/day of clozapine. Treatment efficacy and safety were evaluated with several well-known rating scales. RESULTS: Both risperidone and clozapine significantly reduced the severity of psychotic symptoms (scores on the Positive and Negative Syndrome Scale and the Clinical Global Impression scale) from baseline, with no significant between-group differences. At endpoint, 67% of the risperidone group and 65% of the clozapine group were clinically improved (reduction of 20% or more in total Positive and Negative Syndrome Scale score). Risperidone appeared to have a faster onset of action. In both groups extrapyramidal symptoms and other adverse events were few, and their severity was generally mild. Neither group showed evidence of a relation between drug plasma concentrations and clinical effectiveness. CONCLUSIONS: Risperidone was well tolerated and as effective as medium doses of clozapine in patients with chronic schizophrenia who had been resistant to or intolerant of conventional neuroleptics.

This article has been cited by other articles:

				L. Wang, L. Yu, A.-P. Zhang, C. Fang, J. Du, N.-F. Gu, S.-Y. Qin, G.-Y. Feng, X.-W. Li, Q.-H. Xing, et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia J Psychopharmacol, November 1, 2007; 21(8): 837 - 842. [Abstract] [PDF]

				S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling, and S. Leucht Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics Am J Psychiatry, February 1, 2006; 163(2): 185 - 194. [Abstract] [Full Text] [PDF]

				R. W. Kerwin and A. Bolonna Management of clozapine-resistant schizophrenia Advan. Psychiatr. Treat., March 1, 2005; 11(2): 101 - 106. [Abstract] [Full Text] [PDF]

				J. Tauscher, T. Hussain, O. Agid, N. P. L.G. Verhoeff, A. A. Wilson, S. Houle, G. Remington, R. B. Zipursky, and S. Kapur Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics Am J Psychiatry, September 1, 2004; 161(9): 1620 - 1625. [Abstract] [Full Text] [PDF]

				J. Volavka, P. Czobor, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder Focus, January 1, 2004; 2(1): 59 - 67. [Abstract] [Full Text] [PDF]

				M. Chakos, J. Lieberman, E. Hoffman, D. Bradford, and B. Sheitman Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials Focus, January 1, 2004; 2(1): 111 - 121. [Abstract] [Full Text] [PDF]

				J. M. Davis, N. Chen, and I. D. Glick A Meta-analysis of the Efficacy of Second-Generation Antipsychotics Arch Gen Psychiatry, June 1, 2003; 60(6): 553 - 564. [Abstract] [Full Text] [PDF]

				D. N. OSSER and A. AKHTER Comparative Effectiveness of Antipsychotic Drugs Am J Psychiatry, March 1, 2003; 160(3): 590 - 590. [Full Text]

				H. S. Dinakar, R. N. Sobel, J. H. Bopp, A. Daniels, and S. Mauro Efficacy of Olanzapine and Risperidone for Treatment-Refractory Schizophrenia Among Long-Stay State Hospital Patients Psychiatr Serv, June 1, 2002; 53(6): 755 - 757. [Abstract] [Full Text] [PDF]

				J. Volavka, P. Czobor, B. Sheitman, J.-P. Lindenmayer, L. Citrome, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder Am J Psychiatry, February 1, 2002; 159(2): 255 - 262. [Abstract] [Full Text] [PDF]

				J. M. Kane, S. R. Marder, N. R. Schooler, W. C. Wirshing, D. Umbricht, R. W. Baker, D. A. Wirshing, A. Safferman, R. Ganguli, M. McMeniman, et al. Clozapine and Haloperidol in Moderately Refractory Schizophrenia: A 6-Month Randomized and Double-blind Comparison Arch Gen Psychiatry, October 1, 2001; 58(10): 965 - 972. [Abstract] [Full Text] [PDF]

				J.-M. Azorin, R. Spiegel, G. Remington, J.-M. Vanelle, J.-J. Pere, M. Giguere, and I. Bourdeix A Double-Blind Comparative Study of Clozapine and Risperidone in the Management of Severe Chronic Schizophrenia Am J Psychiatry, August 1, 2001; 158(8): 1305 - 1313. [Abstract] [Full Text] [PDF]

				M. Chakos, J. Lieberman, E. Hoffman, D. Bradford, and B. Sheitman Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials Am J Psychiatry, April 1, 2001; 158(4): 518 - 526. [Abstract] [Full Text]

				I. D. Glick, T. Suppes, C. DeBattista, R. J. Hu, and S. Marder Psychopharmacologic Treatment Strategies for Depression, Bipolar Disorder, and Schizophrenia Ann Intern Med, January 2, 2001; 134(1): 47 - 60. [Abstract] [Full Text] [PDF]

				D. A. Wirshing, B. D. Marshall Jr., M. F. Green, J. Mintz, S. R. Marder, and W. C. Wirshing Risperidone in Treatment-Refractory Schizophrenia Am J Psychiatry, September 1, 1999; 156(9): 1374 - 1379. [Abstract] [Full Text]

				H. Y. MELTZER Risperidone and Clozapine for Treatment-Resistant Schizophrenia Am J Psychiatry, July 1, 1999; 156(7): 1126 - 1127. [Full Text]

				A. F. Breier, A. K. Malhotra, T.-P. Su, D. A. Pinals, I. Elman, C. M. Adler, R. T. Lafargue, A. Clifton, and D. Pickar Clozapine and Risperidone in Chronic Schizophrenia: Effects on Symptoms, Parkinsonian Side Effects, and Neuroendocrine Response Am J Psychiatry, February 1, 1999; 156(2): 294 - 298. [Abstract] [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us